This alliance allows speedier product development and helps Applied Protein Sciences (APS) expand its pipeline to develop drugs for mucositis, proctitis and inflammatory bowel disease. APS expects to
The lead compound in this program, RDEA119, is currently being evaluated in advanced cancer patients as a single agent in a Phase I study and in a Phase
Dr Chin is currently the CEO of Institute for OneWorld Health, a nonprofit pharmaceutical company. Dr Chin joined OneWorld Health from OXiGENE, a developer of vascular targeting drugs
From 1999 to 2004, Mr Baledge served as executive vice president and general counsel for Tyson Foods, a multinational food company. Prior to that, Mr Baledge was counsel
According to Power Medical Interventions (PMI), the iDrive Intelligent Power Unit (IPU), a first-of-its-kind breakthrough in operating room instrumentation, is designed to support a variety of minimally invasive
According to Insulet, the OmniPod insulin management system is the first and only continuous insulin delivery system of its kind in the market. The OmniPod system offers people
The Phase I healthy volunteer study of IMX942 will provide human safety and pharmacodynamic data, said Inimex. IMX942 is the first of a new class of drugs known
Existing investors Aescap Venture, Entrepreneurs Fund and Z-Cube also participated in the series B financing. Regina Hodits of Atlas Venture and Deborah Harland of SR One will join
According to Etex, Beta-bsm and Gamma-bsm set hard to provide an optimal osteoconductive scaffold that mimics the nanocrystalline structure of human bone. Smaller sizes were developed in direct
Sinobiopharma has acquired rights to the following patents – Synthesis of amantadine hydrochloride, method for preparation of 17-acylsinomenine derivatives, preparation of 17-sulfonylsinomenine, preparation of N-substituted sinomenine, method for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.